$MRKR
Marker Therapeutics, Inc.

2020 Q2 Form 10-K Financial Statement

#000110465921033855 Filed on March 09, 2021

View on sec.gov

Income Statement

Concept 2020 Q2 2019 Q4 2019
Revenue $466.8K $210.0K $200.0K
YoY Change -2.91%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.550M $1.910M $9.980M
YoY Change -6.25% -88.88% -59.06%
% of Gross Profit
Research & Development $4.277M $3.660M $12.76M
YoY Change 35.67% -96.92% 60.51%
% of Gross Profit
Depreciation & Amortization $100.0K $40.00K $105.1K
YoY Change 233.33%
% of Gross Profit
Operating Expenses $6.824M $5.580M $22.74M
YoY Change 16.19% -95.89% -84.67%
Operating Profit -$6.358M -$22.53M
YoY Change 8.24% -84.8%
Interest Expense $20.00K $280.0K $1.100M
YoY Change -93.33% -9.68% 423.81%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$6.340M -$5.080M -$21.43M
YoY Change 13.82% -96.25% -85.52%
Income Tax
% Of Pretax Income
Net Earnings -$6.342M -$5.080M -$21.43M
YoY Change 13.85% -96.25% -85.52%
Net Earnings / Revenue -1358.59% -2419.05% -10713.98%
Basic Earnings Per Share
Diluted Earnings Per Share -$136.1K -$111.1K -$470.1K
COMMON SHARES
Basic Shares Outstanding 46.57M 45.59M
Diluted Shares Outstanding

Balance Sheet

Concept 2020 Q2 2019 Q4 2019
SHORT-TERM ASSETS
Cash & Short-Term Investments $32.12M $43.90M $43.90M
YoY Change -39.9% -28.91% -28.91%
Cash & Equivalents $32.10M $43.90M $43.90M
Short-Term Investments
Other Short-Term Assets $2.630M $1.530M $1.530M
YoY Change 436.73% 992.86% 992.86%
Inventory
Prepaid Expenses $2.633M $1.526M
Receivables
Other Receivables $1.000M $0.00
Total Short-Term Assets $34.76M $45.49M $45.49M
YoY Change -35.67% -26.63% -26.63%
LONG-TERM ASSETS
Property, Plant & Equipment $4.221M $418.0K $870.0K
YoY Change 339.69% 183.07% 480.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $13.76M $872.7K $870.0K
YoY Change 1318.91% 490.99% 521.43%
TOTAL ASSETS
Total Short-Term Assets $34.76M $45.49M $45.49M
Total Long-Term Assets $13.76M $872.7K $870.0K
Total Assets $48.52M $46.36M $46.36M
YoY Change -11.78% -25.4% -25.39%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.808M $993.0K $990.0K
YoY Change 95.0% -38.67% -38.89%
Accrued Expenses $2.050M $530.0K $530.0K
YoY Change 109.18% 26.19%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $4.984M $1.993M $1.990M
YoY Change 55.27% -28.92% -28.93%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $9.030M $280.0K $280.0K
YoY Change 2215.38%
Total Long-Term Liabilities $9.025M $280.2K $280.0K
YoY Change 2214.17%
TOTAL LIABILITIES
Total Short-Term Liabilities $4.984M $1.993M $1.990M
Total Long-Term Liabilities $9.025M $280.2K $280.0K
Total Liabilities $14.01M $2.273M $2.270M
YoY Change 290.23% -18.92% -18.93%
SHAREHOLDERS EQUITY
Retained Earnings -$340.4M -$327.5M
YoY Change 7.0%
Common Stock $46.62K $45.73K
YoY Change 0.63%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $34.51M $44.09M $44.09M
YoY Change
Total Liabilities & Shareholders Equity $48.52M $46.36M $46.36M
YoY Change -11.78% -25.4% -25.39%

Cashflow Statement

Concept 2020 Q2 2019 Q4 2019
OPERATING ACTIVITIES
Net Income -$6.342M -$5.080M -$21.43M
YoY Change 13.85% -96.25% -85.52%
Depreciation, Depletion And Amortization $100.0K $40.00K $105.1K
YoY Change 233.33%
Cash From Operating Activities -$4.300M -$4.560M -$18.28M
YoY Change 2.87% -25.97% 26.27%
INVESTING ACTIVITIES
Capital Expenditures -$3.830M -$10.00K -$370.0K
YoY Change 4155.56% -93.33% -350.56%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$3.830M -$10.00K -$375.0K
YoY Change 4155.56% -93.33% 153.94%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $0.00
YoY Change -100.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 0.000 816.5K
YoY Change -100.0% -98.85%
NET CHANGE
Cash From Operating Activities -4.300M -4.560M -18.28M
Cash From Investing Activities -3.830M -10.00K -375.0K
Cash From Financing Activities 0.000 0.000 816.5K
Net Change In Cash -8.130M -4.570M -17.84M
YoY Change 90.4% -107.95% -131.51%
FREE CASH FLOW
Cash From Operating Activities -$4.300M -$4.560M -$18.28M
Capital Expenditures -$3.830M -$10.00K -$370.0K
Free Cash Flow -$470.0K -$4.550M -$17.91M
YoY Change -88.51% -24.29% 22.47%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2020Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
0
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2019Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2019Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2020 dei Entity Central Index Key
EntityCentralIndexKey
0001094038
CY2020 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2020 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2020
CY2020 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2020 dei Amendment Flag
AmendmentFlag
false
CY2019Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
45700000
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
50700000
CY2020 dei Document Type
DocumentType
10-K
CY2020 dei Document Annual Report
DocumentAnnualReport
true
CY2020 dei Document Period End Date
DocumentPeriodEndDate
2020-12-31
CY2020 dei Document Transition Report
DocumentTransitionReport
false
CY2020 dei Entity File Number
EntityFileNumber
001-37939
CY2020 dei Entity Registrant Name
EntityRegistrantName
MARKER THERAPEUTICS, INC.
CY2020 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2020 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
45-4497941
CY2020 dei Entity Address Address Line1
EntityAddressAddressLine1
3200 Southwest Freeway
CY2020 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 2500
CY2020 dei Entity Address City Or Town
EntityAddressCityOrTown
Houston
CY2020 dei Entity Address State Or Province
EntityAddressStateOrProvince
TX
CY2020 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
77027
CY2020 dei City Area Code
CityAreaCode
713
CY2020 dei Local Phone Number
LocalPhoneNumber
400-6400
CY2020 dei Security12b Title
Security12bTitle
Common Stock, par value $0.001 per share
CY2020 dei Trading Symbol
TradingSymbol
MRKR
CY2020 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2020 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2020 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2020 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2020 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2020 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2020 dei Entity Small Business
EntitySmallBusiness
true
CY2020 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2020 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2020 dei Entity Shell Company
EntityShellCompany
false
CY2020Q2 dei Entity Public Float
EntityPublicFloat
64600000
CY2021Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
50731072
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
21352382
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
43903949
CY2020Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
2057924
CY2019Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
1526442
CY2020Q4 us-gaap Interest Receivable
InterestReceivable
559
CY2019Q4 us-gaap Interest Receivable
InterestReceivable
56189
CY2020Q4 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
1000000
CY2019Q4 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
0
CY2020Q4 us-gaap Assets Current
AssetsCurrent
24410865
CY2019Q4 us-gaap Assets Current
AssetsCurrent
45486580
CY2020Q4 mrkr Property Plant And Equipment Other Than Construction In Progress
PropertyPlantAndEquipmentOtherThanConstructionInProgress
3570736
CY2019Q4 mrkr Property Plant And Equipment Other Than Construction In Progress
PropertyPlantAndEquipmentOtherThanConstructionInProgress
417528
CY2020Q4 us-gaap Construction In Progress Gross
ConstructionInProgressGross
6789098
CY2019Q4 us-gaap Construction In Progress Gross
ConstructionInProgressGross
0
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
10844116
CY2019Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
455174
CY2020Q4 us-gaap Assets Noncurrent
AssetsNoncurrent
21203950
CY2020Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
6013010
CY2019Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
1757680
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
388792
CY2019Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
204132
CY2019Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
31000
CY2019Q4 us-gaap Assets Noncurrent
AssetsNoncurrent
872702
CY2020Q4 us-gaap Assets
Assets
45614815
CY2019Q4 us-gaap Assets
Assets
46359282
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
6401802
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1992812
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
11868440
CY2019Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
280247
CY2020Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
11868440
CY2019Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
280247
CY2020Q4 us-gaap Liabilities
Liabilities
18270242
CY2019Q4 us-gaap Liabilities
Liabilities
2273059
CY2019Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2019Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2019Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
50700000
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
45700000
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
50731
CY2019Q4 us-gaap Common Stock Value
CommonStockValue
45728
CY2020Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
383533326
CY2019Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
371573909
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-356239484
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-327533414
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
27344573
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
44086223
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
45614815
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
46359282
CY2020 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
466785
CY2019 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
213194
CY2020 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
18880751
CY2019 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
12764804
CY2020 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
10471846
CY2019 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9977196
CY2020 us-gaap Operating Expenses
OperatingExpenses
29352597
CY2019 us-gaap Operating Expenses
OperatingExpenses
22742000
CY2020 us-gaap Operating Income Loss
OperatingIncomeLoss
-28885812
CY2019 us-gaap Operating Income Loss
OperatingIncomeLoss
-22528806
CY2020 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
31000
CY2019 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
18000
CY2020 us-gaap Investment Income Interest
InvestmentIncomeInterest
148742
CY2019 us-gaap Investment Income Interest
InvestmentIncomeInterest
1082842
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-28706070
CY2019 us-gaap Net Income Loss
NetIncomeLoss
-21427964
CY2020 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.61
CY2019 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.47
CY2020 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
47039862
CY2019 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
45587734
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
59340738
CY2019 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
57744
CY2019 mrkr Exercise Of Warrants Amount
ExerciseOfWarrantsAmount
758733
CY2019 mrkr Warrant Of Cash Less Exercised
WarrantOfCashLessExercised
0
CY2019 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
5356972
CY2019 us-gaap Net Income Loss
NetIncomeLoss
-21427964
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
44086223
CY2020 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
6186011
CY2020 mrkr Exercise Of Warrants Amount
ExerciseOfWarrantsAmount
550000
CY2020 mrkr Issuance Of Common Stock Value As Commitment Fee For Future Financing
IssuanceOfCommonStockValueAsCommitmentFeeForFutureFinancing
0
CY2020 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
5228409
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-28706070
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
27344573
CY2020 us-gaap Profit Loss
ProfitLoss
-28706070
CY2019 us-gaap Profit Loss
ProfitLoss
-21427964
CY2020 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
485641
CY2019 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
105123
CY2020 us-gaap Increase Decrease In Derivative Liabilities
IncreaseDecreaseInDerivativeLiabilities
-31000
CY2019 us-gaap Increase Decrease In Derivative Liabilities
IncreaseDecreaseInDerivativeLiabilities
-18000
CY2020 us-gaap Share Based Compensation
ShareBasedCompensation
5228409
CY2019 us-gaap Share Based Compensation
ShareBasedCompensation
5356972
CY2020 mrkr Amortization Of Operating Lease Right Of Use Assets
AmortizationOfOperatingLeaseRightOfUseAssets
590039
CY2019 mrkr Amortization Of Operating Lease Right Of Use Assets
AmortizationOfOperatingLeaseRightOfUseAssets
181459
CY2020 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
531482
CY2019 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
1384725
CY2020 us-gaap Increase Decrease In Accrued Interest Receivable Net
IncreaseDecreaseInAccruedInterestReceivableNet
-55630
CY2019 us-gaap Increase Decrease In Accrued Interest Receivable Net
IncreaseDecreaseInAccruedInterestReceivableNet
-51988
CY2020 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
4222470
CY2019 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-963967
CY2020 mrkr Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-173268
CY2019 mrkr Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-185179
CY2020 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-18859631
CY2019 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-18284293
CY2020 mrkr Payments To Acquire Property Plant And Equipment Excluding Construction In Progress
PaymentsToAcquirePropertyPlantAndEquipmentExcludingConstructionInProgress
3638849
CY2019 mrkr Payments To Acquire Property Plant And Equipment Excluding Construction In Progress
PaymentsToAcquirePropertyPlantAndEquipmentExcludingConstructionInProgress
374983
CY2020 us-gaap Payments For Construction In Process
PaymentsForConstructionInProcess
6789098
CY2019 us-gaap Payments For Construction In Process
PaymentsForConstructionInProcess
0
CY2020 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-10427947
CY2019 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-374983
CY2020 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
6186011
CY2019 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0
CY2020 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
0
CY2019 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
57744
CY2020 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
550000
CY2019 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
758733
CY2020 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
6736011
CY2019 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
816477
CY2020 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-22551567
CY2019 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-17842799
CY2019Q4 us-gaap Cash
Cash
43903949
CY2018Q4 us-gaap Cash
Cash
61746748
CY2020Q4 us-gaap Cash
Cash
21352382
CY2019Q4 us-gaap Cash
Cash
43903949
CY2020 mrkr Non Cash Issuance Of Common Stock As Commitment Fee For Future Financing
NonCashIssuanceOfCommonStockAsCommitmentFeeForFutureFinancing
345
CY2019 mrkr Non Cash Issuance Of Common Stock As Commitment Fee For Future Financing
NonCashIssuanceOfCommonStockAsCommitmentFeeForFutureFinancing
0
CY2020 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
11114300
CY2019 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0
CY2020 mrkr Non Cash Exercise Of Warrants Amount
NonCashExerciseOfWarrantsAmount
0
CY2019 mrkr Non Cash Exercise Of Warrants Amount
NonCashExerciseOfWarrantsAmount
9
CY2020 us-gaap Nature Of Operations
NatureOfOperations
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">NOTE 1:    NATURE OF OPERATIONS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Marker Therapeutics, Inc., a Delaware corporation (the “Company” or “we”), is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and innovative peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The Company’s MultiTAA-specific T cell technology is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor associated antigens, which are tumor targets, and kill tumor cells expressing those targets. These T cells are designed to recognize multiple tumor targets to produce broad spectrum anti-tumor activity. The Company was incorporated in Nevada in 1992 and reincorporated in Delaware in October 2018.</p>
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
21400000
CY2020 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Preparation of the Company’s consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect certain reported amounts and disclosures. Accordingly, actual results could differ materially from those estimates. Significant areas requiring management’s estimates and assumptions include valuation allowance on deferred tax assets, determining the fair value of stock-based compensation and stock-based transactions, the fair value of the components of the warrant liabilities and accrued liabilities.</p>
CY2020Q4 us-gaap Cash Fdic Insured Amount
CashFDICInsuredAmount
250000
CY2020Q4 us-gaap Cash Uninsured Amount
CashUninsuredAmount
2700000
CY2020 us-gaap Property Plant And Equipment Estimated Useful Lives
PropertyPlantAndEquipmentEstimatedUsefulLives
the straight-line method over the estimated useful lives of the related assets, which range from three to five years
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-28706070
CY2019 us-gaap Net Income Loss
NetIncomeLoss
-21427964
CY2020 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
47039862
CY2019 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
45587734
CY2020 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.61
CY2019 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.47
CY2020 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
26832000
CY2019 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
27647000
CY2020Q4 us-gaap Tenant Improvements
TenantImprovements
1000000.0
CY2020Q4 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
1000000.0
CY2021Q2 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
1000000.0
CY2020Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
4162000
CY2019Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
523000
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
591000
CY2019Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
105000
CY2020Q4 us-gaap Construction In Progress Gross
ConstructionInProgressGross
6789000
CY2019Q4 us-gaap Construction In Progress Gross
ConstructionInProgressGross
0
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
10360000
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
418000
CY2020 us-gaap Depreciation
Depreciation
500000
CY2019 us-gaap Depreciation
Depreciation
100000
CY2020Q4 us-gaap Construction In Progress Gross
ConstructionInProgressGross
6800000
CY2020Q2 us-gaap Leasehold Improvements Gross
LeaseholdImprovementsGross
300000
CY2021Q3 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P10Y
CY2020Q3 mrkr Number Of Renewal Options
NumberOfRenewalOptions
2
CY2020Q3 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P5Y
CY2020Q3 mrkr Fixed Lease Rent Payment
FixedLeaseRentPayment
5600000
CY2020Q2 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P71M
CY2020Q2 mrkr Fixed Lease Rent Payment
FixedLeaseRentPayment
1100000
CY2020Q2 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P10Y
CY2020Q2 mrkr Number Of Renewal Options
NumberOfRenewalOptions
2
CY2020Q2 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P5Y
CY2020Q2 mrkr Fixed Lease Rent Payment
FixedLeaseRentPayment
9800000
CY2020Q2 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
1000000.0
CY2020Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
12300000
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
10800000
CY2020 us-gaap Operating Lease Cost
OperatingLeaseCost
960000
CY2019 us-gaap Operating Lease Cost
OperatingLeaseCost
220000
CY2019Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
94000
CY2020Q4 mrkr Accrued Technology License Fees
AccruedTechnologyLicenseFees
105000
CY2020 us-gaap Short Term Lease Cost
ShortTermLeaseCost
22000
CY2019 us-gaap Short Term Lease Cost
ShortTermLeaseCost
100000
CY2020 us-gaap Variable Lease Cost
VariableLeaseCost
167000
CY2019 us-gaap Variable Lease Cost
VariableLeaseCost
90000
CY2020 us-gaap Lease Cost
LeaseCost
1149000
CY2019 us-gaap Lease Cost
LeaseCost
410000
CY2020 us-gaap Operating Lease Payments
OperatingLeasePayments
544000
CY2019 us-gaap Operating Lease Payments
OperatingLeasePayments
225000
CY2020Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P9Y3M18D
CY2019Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P1Y7M6D
CY2020Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.057
CY2019Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.068
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
1077000
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
1278000
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
1542000
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
1826000
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
1874000
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
8772000
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
16369000
CY2020Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
4112000
CY2020Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
12257000
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2935000
CY2019Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
993000
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1694000
CY2019Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
323000
CY2020Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
875000
CY2019Q4 mrkr Accrued Technology License Fees
AccruedTechnologyLicenseFees
105000
CY2020Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
20830000
CY2020Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
404000
CY2019Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
243000
CY2020Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
6013000
CY2019Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
1758000
CY2018Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
49000
CY2019 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Period Increase Decrease
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease
-18000
CY2019Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
31000
CY2020 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Period Increase Decrease
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease
-31000
CY2020Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
0
CY2019 mrkr Fair Value Transfers Amount
FairValueTransfersAmount
0
CY2020 mrkr Fair Value Transfers Amount
FairValueTransfersAmount
0
CY2019Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2019Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020 us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
600000
CY2018Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
23016000
CY2018Q4 mrkr Class Of Warrant Or Rights Outstanding Weighted Average Exercise Price
ClassOfWarrantOrRightsOutstandingWeightedAverageExercisePrice
4.78
CY2018 mrkr Class Of Warrant Or Rights Outstanding Weighted Average Remaining Contractual Life
ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualLife
P4Y3M14D
CY2018Q4 mrkr Class Of Warrant Or Right Outstanding Intrinsic Value
ClassOfWarrantOrRightOutstandingIntrinsicValue
26066000
CY2019 mrkr Number Of Warrants Granted
NumberOfWarrantsGranted
45000
CY2019 mrkr Class Of Warrant Or Rights Outstanding Warrants Granted Weighted Average Exercise Price
ClassOfWarrantOrRightsOutstandingWarrantsGrantedWeightedAverageExercisePrice
4.26
CY2019 mrkr Number Of Warrant Exercised For Cash
NumberOfWarrantExercisedForCash
190000
CY2019 mrkr Class Of Warrant Or Rights Outstanding Exercised Weighted Average Exercised For Cash
ClassOfWarrantOrRightsOutstandingExercisedWeightedAverageExercisedForCash
3.99
CY2019 mrkr Number Of Warrant Cashless Exercised
NumberOfWarrantCashlessExercised
17000
CY2019 mrkr Class Of Warrant Or Rights Outstanding Exercised Weighted Average Exercise Price Cashless Exercised
ClassOfWarrantOrRightsOutstandingExercisedWeightedAverageExercisePriceCashlessExercised
2.38
CY2019 mrkr Number Of Warrant Expired Or Cancelled
NumberOfWarrantExpiredOrCancelled
190000
CY2019 mrkr Class Of Warrant Or Rights Outstanding Expired Or Cancelled Weighted Average Exercise Price
ClassOfWarrantOrRightsOutstandingExpiredOrCancelledWeightedAverageExercisePrice
13.63
CY2019Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
22664000
CY2019Q4 mrkr Class Of Warrant Or Rights Outstanding Weighted Average Exercise Price
ClassOfWarrantOrRightsOutstandingWeightedAverageExercisePrice
4.71
CY2020 mrkr Class Of Warrant Or Rights Outstanding Expired Or Cancelled Weighted Average Exercise Price
ClassOfWarrantOrRightsOutstandingExpiredOrCancelledWeightedAverageExercisePrice
9.46
CY2019 mrkr Class Of Warrant Or Rights Outstanding Weighted Average Remaining Contractual Life
ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualLife
P3Y3M29D
CY2019Q4 mrkr Class Of Warrant Or Right Outstanding Intrinsic Value
ClassOfWarrantOrRightOutstandingIntrinsicValue
954000
CY2020 mrkr Number Of Warrant Exercised For Cash
NumberOfWarrantExercisedForCash
458000
CY2020 mrkr Class Of Warrant Or Rights Outstanding Exercised Weighted Average Exercised For Cash
ClassOfWarrantOrRightsOutstandingExercisedWeightedAverageExercisedForCash
1.20
CY2020 mrkr Number Of Warrant Expired Or Cancelled
NumberOfWarrantExpiredOrCancelled
1376000
CY2020Q4 mrkr Class Of Warrant Or Rights Outstanding Weighted Average Exercise Price
ClassOfWarrantOrRightsOutstandingWeightedAverageExercisePrice
4.47
CY2020 mrkr Class Of Warrant Or Rights Outstanding Weighted Average Remaining Contractual Life
ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualLife
P2Y7M6D
CY2020Q4 us-gaap Class Of Warrant Or Right Number Of Securities Called By Each Warrant Or Right
ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
500000
CY2020 us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
600000
CY2019Q4 us-gaap Class Of Warrant Or Right Number Of Securities Called By Each Warrant Or Right
ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
200000
CY2019 us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
800000
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period
SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
P10Y
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
P4Y
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
P4Y
CY2020Q4 mrkr Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Options Availble For Issued
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesOptionsAvailbleForIssued
4700000
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
2.08
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
4.70
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
CY2019 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.08
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.26
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.01
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.02
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2020 us-gaap Share Based Compensation
ShareBasedCompensation
5228000
CY2019 us-gaap Share Based Compensation
ShareBasedCompensation
5357000
CY2020Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
10600000
CY2020 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y2M12D
CY2020 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
500000
CY2019 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
200000
CY2020 mrkr Loss Contingency Damages Sought Number Of Transactions
LossContingencyDamagesSoughtNumberOfTransactions
2
CY2020 us-gaap Loss Contingency Damages Sought Value
LossContingencyDamagesSoughtValue
1000000.0
CY2020 us-gaap Related Party Transaction Expenses From Transactions With Related Party
RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
1970000
CY2019 us-gaap Related Party Transaction Expenses From Transactions With Related Party
RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
353000
CY2020Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
21783000
CY2019Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
17166000
CY2020Q4 mrkr Deferredtaxstockbasedcompensation
Deferredtaxstockbasedcompensation
6775000
CY2019Q4 mrkr Deferredtaxstockbasedcompensation
Deferredtaxstockbasedcompensation
6538000
CY2020Q4 mrkr Deferredtaxassetslicenseagreement
Deferredtaxassetslicenseagreement
144000
CY2019Q4 mrkr Deferredtaxassetslicenseagreement
Deferredtaxassetslicenseagreement
177000
CY2020Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
733000
CY2019Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
733000
CY2020Q4 us-gaap Deferred Tax Assets Charitable Contribution Carryforwards
DeferredTaxAssetsCharitableContributionCarryforwards
8000
CY2019Q4 us-gaap Deferred Tax Assets Charitable Contribution Carryforwards
DeferredTaxAssetsCharitableContributionCarryforwards
9000
CY2020 mrkr Operating Loss Carryforwards Limitation Percentage
OperatingLossCarryforwardsLimitationPercentage
0.80
CY2019Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards State And Local
DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
21900000
CY2020 mrkr Operating Loss Carryforwards Limitation Percentage
OperatingLossCarryforwardsLimitationPercentage
0.80
CY2020 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-6028000
CY2020 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.2100
CY2020Q4 mrkr Deferred Tax Assets Operating Lease Liability
DeferredTaxAssetsOperatingLeaseLiability
2626000
CY2019Q4 mrkr Deferred Tax Assets Operating Lease Liability
DeferredTaxAssetsOperatingLeaseLiability
115000
CY2020Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
32069000
CY2019Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
24738000
CY2020Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
29689000
CY2019Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
24632000
CY2020Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
2380000
CY2019Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
106000
CY2019Q4 mrkr Deferred Tax Liabilities Fixed Assets
DeferredTaxLiabilitiesFixedAssets
106000
CY2020Q4 mrkr Deferred Tax Liabilities Right Of Use Assets
DeferredTaxLiabilitiesRightOfUseAssets
2380000
CY2020Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
2380000
CY2019Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
106000
CY2020 mrkr Decreased Deferred Tax Assets
DecreasedDeferredTaxAssets
5100000
CY2020Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
700000
CY2020Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards Foreign
DeferredTaxAssetsOperatingLossCarryforwardsForeign
97200000
CY2020Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards State And Local
DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
39000000.0
CY2019Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards Foreign
DeferredTaxAssetsOperatingLossCarryforwardsForeign
41600000
CY2020 mrkr Taxcreditcarryforwardexpirationyearrangestart
Taxcreditcarryforwardexpirationyearrangestart
2029
CY2020 mrkr Taxcreditcarryforwardexpirationyearrangeend
Taxcreditcarryforwardexpirationyearrangeend
2037
CY2019 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-4500000
CY2019 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.2100
CY2020 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-118000
CY2020 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.0041
CY2019 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-600000
CY2019 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.0280
CY2020 us-gaap Income Tax Reconciliation Change In Enacted Tax Rate
IncomeTaxReconciliationChangeInEnactedTaxRate
677000
CY2020 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
-0.0236
CY2019 us-gaap Income Tax Reconciliation Change In Enacted Tax Rate
IncomeTaxReconciliationChangeInEnactedTaxRate
665000
CY2019 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
-0.0310
CY2020 mrkr Incometaxreconciliationchangeinfairvalueofderivativeliability
Incometaxreconciliationchangeinfairvalueofderivativeliability
-7000
CY2020 mrkr Effective Income Tax Rate Reconciliation Change In Fair Value Of Derivative Liability
EffectiveIncomeTaxRateReconciliationChangeInFairValueOfDerivativeLiability
0.0002
CY2019 mrkr Incometaxreconciliationchangeinfairvalueofderivativeliability
Incometaxreconciliationchangeinfairvalueofderivativeliability
-4000
CY2019 mrkr Effective Income Tax Rate Reconciliation Change In Fair Value Of Derivative Liability
EffectiveIncomeTaxRateReconciliationChangeInFairValueOfDerivativeLiability
0.0002
CY2020 mrkr Permanentdifferencesotherpermanentdifferences
Permanentdifferencesotherpermanentdifferences
-182000
CY2020 mrkr Effective Income Tax Rate Reconciliation Other Permanent Differences
EffectiveIncomeTaxRateReconciliationOtherPermanentDifferences
-0.0063
CY2019 mrkr Permanentdifferencesotherpermanentdifferences
Permanentdifferencesotherpermanentdifferences
-32000
CY2019 mrkr Effective Income Tax Rate Reconciliation Other Permanent Differences
EffectiveIncomeTaxRateReconciliationOtherPermanentDifferences
-0.0015
CY2020 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
-5057000
CY2020 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.1762
CY2019 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
-4681000
CY2019 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.2185
CY2020 us-gaap Income Tax Reconciliation Other Reconciling Items
IncomeTaxReconciliationOtherReconcilingItems
237000
CY2020 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.0083
CY2019 us-gaap Income Tax Reconciliation Other Reconciling Items
IncomeTaxReconciliationOtherReconcilingItems
-274000
CY2019 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0.0128
CY2020 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.0000
CY2019 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.0000

Files In Submission

Name View Source Status
0001104659-21-033855-index-headers.html Edgar Link pending
0001104659-21-033855-index.html Edgar Link pending
0001104659-21-033855.txt Edgar Link pending
0001104659-21-033855-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
mrkr-20201231.xsd Edgar Link pending
mrkr-20201231x10k.htm Edgar Link pending
mrkr-20201231x10k001.jpg Edgar Link pending
mrkr-20201231x10k002.jpg Edgar Link pending
mrkr-20201231x10k003.jpg Edgar Link pending
mrkr-20201231x10k004.jpg Edgar Link pending
mrkr-20201231x10k005.jpg Edgar Link pending
mrkr-20201231x10k006.jpg Edgar Link pending
mrkr-20201231x10k007.jpg Edgar Link pending
mrkr-20201231x10k008.jpg Edgar Link pending
mrkr-20201231x10k009.jpg Edgar Link pending
mrkr-20201231x10k010.jpg Edgar Link pending
mrkr-20201231x10k011.jpg Edgar Link pending
mrkr-20201231x10k_htm.xml Edgar Link completed
mrkr-20201231xex21d1.htm Edgar Link pending
mrkr-20201231xex23d1.htm Edgar Link pending
mrkr-20201231xex31d1.htm Edgar Link pending
mrkr-20201231xex31d2.htm Edgar Link pending
mrkr-20201231xex32d1.htm Edgar Link pending
mrkr-20201231xex32d2.htm Edgar Link pending
mrkr-20201231_cal.xml Edgar Link unprocessable
mrkr-20201231_def.xml Edgar Link unprocessable
mrkr-20201231_lab.xml Edgar Link unprocessable
mrkr-20201231_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending